Silence Therapeutics Announces Topline 48-Week Data Phase 2 Zerlasiran Study Showing Sustained Reductions In Lp(a) To Week 48
Portfolio Pulse from Benzinga Newsdesk
Silence Therapeutics announced positive topline 48-week data from its Phase 2 Zerlasiran study, showing sustained reductions in Lp(a) levels through Week 48.
June 20, 2024 | 11:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Silence Therapeutics announced positive topline 48-week data from its Phase 2 Zerlasiran study, showing sustained reductions in Lp(a) levels through Week 48.
The positive data from the Phase 2 study is likely to boost investor confidence in Silence Therapeutics' pipeline, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100